The anatomic pathology market is projected to grow significantly, reaching approximately USD 21.39 billion by 2031, up from USD 12.69 billion in 2023. This growth represents a compound annual growth rate (CAGR) of 6.7% from 2023 to 2031.
1. Products and Services: The market is categorized into services, instruments, and consumables. In 2023, instruments accounted for the largest market share. The services segment is further divided into histopathology and cytopathology, while the instruments segment includes microtomes, cryostats, automatic stainers, tissue processors, and other related tools.
2. Applications: The market is segmented by application into disease diagnosis, drug discovery and development, and other areas. The disease diagnosis segment held the largest share in 2023, reflecting the critical role of anatomic pathology in identifying various diseases.
3. End Users: The end-user segmentation includes hospitals, research laboratories, diagnostic laboratories, and others. Hospitals represented the largest share of the market in 2023, highlighting their central role in the delivery of anatomic pathology services.
Moreover, the US has witnessed remarkable advancements in medical technologies, leading to the development of sophisticated medical devices within the healthcare sector. Companies in the US anatomic pathology market are focused on creating innovative and user-friendly instruments and consumables for pathological procedures. For instance, in November 2023, Illumina Inc. launched a new version of its liquid biopsy assay, TruSight Oncology 500 ctDNA v2, which allows for comprehensive noninvasive genomic profiling of circulating tumor DNA from blood samples, complementing traditional tissue-based testing. In 2020, F. Hoffmann-La Roche received FDA approval for the expanded use of the CINtec PLUS Cytology test, aiding in cervical cancer prevention.
These factors, including the high cancer prevalence, the presence of major industry players, and the availability of high-quality infrastructure for hospitals and clinical laboratories, are expected to further bolster the growth of the anatomic pathology market in the US.
Reasons to Buy
Executive Summary and North America Anatomic Pathology Market Overview
In North America, the anatomic pathology market is divided into three main regions: the United States, Canada, and Mexico. This region is recognized as a major player in the anatomic pathology sector, primarily due to the increasing incidence of cancer, enhanced government initiatives aimed at cancer screening, a growing emphasis on accurate disease diagnosis, and the rising demand for advanced healthcare systems. Additionally, the market is expected to benefit from heightened research and development activities by key industry players, along with the introduction of new products, which are anticipated to propel the growth of the anatomic pathology market in North America throughout the forecast period.North America Anatomic Pathology Market Segmentation Analysis
The analysis of the North American anatomic pathology market is based on several key segments, including products and services, applications, and end users.1. Products and Services: The market is categorized into services, instruments, and consumables. In 2023, instruments accounted for the largest market share. The services segment is further divided into histopathology and cytopathology, while the instruments segment includes microtomes, cryostats, automatic stainers, tissue processors, and other related tools.
2. Applications: The market is segmented by application into disease diagnosis, drug discovery and development, and other areas. The disease diagnosis segment held the largest share in 2023, reflecting the critical role of anatomic pathology in identifying various diseases.
3. End Users: The end-user segmentation includes hospitals, research laboratories, diagnostic laboratories, and others. Hospitals represented the largest share of the market in 2023, highlighting their central role in the delivery of anatomic pathology services.
North America Anatomic Pathology Market Outlook
Companies, both large and small, operating within the anatomic pathology market are increasingly implementing various strategies such as geographic expansion, launching new products, and advancing technology to enhance their revenue streams. Recent developments in the market include:- May 2024: Quest Diagnostics and PathAI announced a collaboration aimed at accelerating the integration of digital and AI pathology innovations to enhance the quality, speed, and efficiency of cancer and disease diagnoses. As part of this agreement, Quest will acquire specific assets from PathAI Diagnostics, which specializes in digital and anatomic pathology laboratory services.
- April 2024: Medline became the distributor for Epredia, a member of the PHC Group, which offers solutions for precision cancer diagnostics and tissue diagnostics in the anatomic pathology sector. This partnership allows Medline to expand its portfolio of laboratory products and equipment.
- April 2024: StatLab Medical Products acquired Scientific Device Laboratory, a Chicago-based manufacturer of diagnostic slides and consumables for anatomic pathology and microbiology. This acquisition enhances StatLab's manufacturing capabilities and market presence.
- February 2024: Hologic Inc received FDA approval for its Genius Digital Diagnostics System, a cutting-edge digital cytology system designed for pap testing, which is set to launch in the US in 2024 after being available in Europe, Australia, and New Zealand.
North America Anatomic Pathology Market Country Insights
The North American anatomic pathology market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. Cancer remains a major public health concern in the US, with prevalent types including breast, lung, prostate, colon, and liver cancers. According to the National Cancer Institute, approximately 17.43 million individuals were living with cancer in the US as of 2021, with projections indicating that the number of cancer survivors could reach 22.2 million by 2030. This increasing prevalence of cancer is expected to drive demand for various pathologic diagnostic tests, including biopsies, fine-needle aspirations, genetic testing, and other innovative techniques.Moreover, the US has witnessed remarkable advancements in medical technologies, leading to the development of sophisticated medical devices within the healthcare sector. Companies in the US anatomic pathology market are focused on creating innovative and user-friendly instruments and consumables for pathological procedures. For instance, in November 2023, Illumina Inc. launched a new version of its liquid biopsy assay, TruSight Oncology 500 ctDNA v2, which allows for comprehensive noninvasive genomic profiling of circulating tumor DNA from blood samples, complementing traditional tissue-based testing. In 2020, F. Hoffmann-La Roche received FDA approval for the expanded use of the CINtec PLUS Cytology test, aiding in cervical cancer prevention.
These factors, including the high cancer prevalence, the presence of major industry players, and the availability of high-quality infrastructure for hospitals and clinical laboratories, are expected to further bolster the growth of the anatomic pathology market in the US.
North America Anatomic Pathology Market Company Profiles
Key players in the North American anatomic pathology market include F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, and PHC Holdings Corporation, among others. These companies are actively pursuing strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase their market share.Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America anatomic pathology market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America anatomic pathology market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the anatomic pathology market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Anatomic Pathology Market Landscape
5. North America Anatomic Pathology Market - Key Market Dynamics
6. Anatomic Pathology Market - North America Analysis
7. North America Anatomic Pathology Market Analysis - by Product and Services
8. North America Anatomic Pathology Market Analysis - by Application
9. North America Anatomic Pathology Market Analysis - by End User
10. North America Anatomic Pathology Market - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Beckman Coulter Inc
- Hologic Inc
- Agilent Technologies Inc
- BioGenex Laboratories Inc
- Diapath S.p.A.
- Bio SB
- Merck KGaA
- PHC Holdings Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 127 |
Published | July 2025 |
Forecast Period | 2023 - 2031 |
Estimated Market Value in 2023 | 12692.48 Million |
Forecasted Market Value by 2031 | 21398.45 Million |
Compound Annual Growth Rate | 6.7% |
Regions Covered | North America |
No. of Companies Mentioned | 9 |